p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell.
Tessoulin B et al. Blood Rev. 2017 Mar 4. pii: S0268-960X(16)30059-5. doi: 10.1016/j.blre.2017.03.001. [Epub ahead of print].
Mesenchymal stromal cells enhance the suppressive effects ofmyeloid-derived suppressor cells of multiple myeloma.
Xu Y et al. Leuk Lymphoma. 2017 Mar 20:1-9. doi: 10.1080/10428194.2017.1298753. [Epub ahead of print].
Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.
Gao H et al. Int J Hematol. 2017 Mar 18. doi: 10.1007/s12185-017-2216-2. [Epub ahead of print].
T-cell Bispecific Antibodies Suppress Multiple Myeloma.
[No authors listed]. Cancer Discov. 2017 Mar 17. doi: 10.1158/2159-8290.CD-RW2017-054. [Epub ahead of print].
MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells.
Sanyal R et al. Immunol Cell Biol. 2017 Mar 17. doi: 10.1038/icb.2017.18. [Epub ahead of print].
LncRNA MALAT-1 Elevates HMGB1 to Promote Autophagy Resulting in Inhibition of Tumor Cell Apoptosis in Multiple Myeloma.
Gao D et al. J Cell Biochem. 2017 Mar 11. doi: 10.1002/jcb.25987. [Epub ahead of print].
Crocin Suppresses Constitutively Active STAT3 through Induction of Protein Tyrosine Phosphatase SHP-1.
Kim B et al. J Cell Biochem. 2017 Mar 10. doi: 10.1002/jcb.25980. [Epub ahead of print].
Antibodies Create Killer Bonds in Myeloma.
Chesi M et al. Cancer Cell. 2017 Mar 13;31(3):305-307. doi: 10.1016/j.ccell.2017.02.011.
Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling.
Gupta N et al. Clin Pharmacokinet. 2017 Mar 13. doi: 10.1007/s40262-017-0526-4. [Epub ahead of print].
Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex).
Sanchez E et al. Leuk Res. 2017 Mar 6;57:45-54. doi: 10.1016/j.leukres.2017.03.002. [Epub ahead of print].
Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement.
Schuh E et al. J Immunol. 2017 Mar 10. pii: 1601746. doi: 10.4049/jimmunol.1601746. [Epub ahead of print].
PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.
Piddock RE et al. Blood Cancer J. 2017 Mar 10;7(3):e539. doi: 10.1038/bcj.2017.16.
Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.
Carballo-Zarate AA et al. Mod Pathol. 2017 Mar 10. doi: 10.1038/modpathol.2017.3. [Epub ahead of print].
Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network.
Zheng Z et al. Onco Targets Ther. 2017 Mar 1;10:1327-1334. doi: 10.2147/OTT.S130742. eCollection 2017.
High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma.
Bernardini G et al. Leuk Lymphoma. 2017 Feb 28:1-4. doi: 10.1080/10428194.2017.1295144. [Epub ahead of print].
Long Non-coding RNA CRNDE Promotes Multiple Myeloma Cell Growth By Suppressing MiR-451.
Meng YB et al. Oncol Res. 2017 Mar 9. doi: 10.3727/096504017X14886679715637. [Epub ahead of print].
Smenospongidine suppresses the proliferation of multiple myeloma cells by promoting CCAAT/enhancer-binding protein homologous protein-mediated β-catenin degradation.
Park S et al. Arch Pharm Res. 2017 Mar 8. doi: 10.1007/s12272-017-0906-1. [Epub ahead of print].
Effect and mechanism of curcumin on EZH2 – miR-101 regulatory feedback loop in multiple myeloma.
Wu C et al. Curr Pharm Des. 2017 Mar 17. doi: 10.2174/1381612823666170317164639. [Epub ahead of print].
Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice.
Park JE et al. PLoS One. 2017 Mar 8;12(3):e0173247. doi: 10.1371/journal.pone.0173247. eCollection 2017.
Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.
Das DS et al. Clin Cancer Res. 2017 Mar 7. pii: clincanres.2692.2016. doi: 10.1158/1078-0432.CCR-16-2692. [Epub ahead of print].
Tumor Cell-Derived Microvesicles Induced Not Epithelial-Mesenchymal Transition but Apoptosis in Human Proximal Tubular (HK-2) Cells: Implications for Renal Impairment in Multiple Myeloma.
Zhao A et al. Int J Mol Sci. 2017 Feb 27;18(3). pii: E513. doi: 10.3390/ijms18030513.
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.
North BJ et al. PLoS One. 2017 Mar 6;12(3):e0173507. doi: 10.1371/journal.pone.0173507. eCollection 2017.
NCOA1 is a novel susceptibility gene for multiple myeloma in the Chinese population: A case-control study.
Peng M et al. PLoS One. 2017 Mar 6;12(3):e0173298. doi: 10.1371/journal.pone.0173298. eCollection 2017.
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.
Tumber A et al. Cell Chem Biol. 2017 Mar 16;24(3):371-380. doi: 10.1016/j.chembiol.2017.02.006. Epub 2017 Mar 2.
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.
Li J et al. Cancer Cell. 2017 Mar 13;31(3):383-395. doi: 10.1016/j.ccell.2017.02.001. Epub 2017 Mar 2.
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.
Seckinger A et al. Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2.
Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3.
Hiasa M et al. Cancer Res. 2017 Mar 15;77(6):1283-1295. doi: 10.1158/0008-5472.CAN-15-3545. Epub 2017 Mar 2.
Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.
Asimakopoulos F et al. J Leukoc Biol. 2017 Mar 2. pii: jlb.3MR1116-468R. doi: 10.1189/jlb.3MR1116-468R. [Epub ahead of print].
Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma.
Feng X et al. Clin Cancer Res. 2017 Mar 1. pii: clincanres.3192.2016. doi: 10.1158/1078-0432.CCR-16-3192. [Epub ahead of print].
Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11.
Li J et al. Nat Chem Biol. 2017 Feb 28. doi: 10.1038/nchembio.2326. [Epub ahead of print].
A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo.
Lwin ST et al. Mol Cancer. 2017 Feb 28;16(1):49. doi: 10.1186/s12943-017-0616-9.
Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.
Bai L et al. J Transl Med. 2017 Feb 27;15(1):51. doi: 10.1186/s12967-017-1152-5.
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.
Martinez-Lopez J et al. Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.58. [Epub ahead of print].
RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma.
Viziteu E et al. Leukemia. 2017 Mar 10. doi: 10.1038/leu.2017.54. [Epub ahead of print].